Immunotherapy has been shown to prolong OS by about 4 months versus chemotherapy in MM [9], however, the predictive role of PD‐L1 for immunotherapy efficacy was controversial [35]; 77.8% patients of this study had a PD‐L1 positivity (PD‐L1 TPS ≥ 1%), much higher than the 18%–24% of a large international cohort [35]. This evidence concerns the gene CD274 and Miyoshi myopathy.